Organization (Hospital)
East and North Hertfordshire NHS Trust
ClinicalTrials.gov lists East and North Hertfordshire NHS Trust as lead sponsor of 36 trials. It has 1 active development program and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers East and North Hertfordshire NHS Trust: 36 lead-sponsored trials and 1 legal-entity registration.
Disease areas (63)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Atrial Fibrillation | 5 |
| Breast Neoplasms | 5 |
| Head and Neck Neoplasms | 4 |
| Prostatic Neoplasms | 4 |
| Renal Insufficiency, Chronic | 4 |
Showing 5 of 63 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 5 |
| 2024 | 4 |
| 2023 | 7 |
| 2022 | 3 |
| 2020 | 1 |
| 2019 | 4 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 3 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Blood Test | Aortic Valve Stenosis | Not reported | 1 |
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Clopidogrel 75Mg Tablet | 1 |
| Ticagrelor 90Mg Tablet | 1 |
| Rivaroxaban 2.5Mg Tablet | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 57% hit target (n=7) | 25% on time (n=8) |
Journals published in (74)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| BMJ open | 3 |
| PloS one | 3 |
| BMJ (Clinical research ed.) | 2 |
| Chest | 2 |
| European heart journal | 2 |
Showing 5 of 74 journals.
Organization relationships (46)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Imperial College Healthcare NHS Trust | Co sponsors trial with | 3 |
| Cancer Research UK | Co sponsors trial with | 2 |
| Oxford University Hospitals NHS Trust | Co sponsors trial with | 2 |
| The Christie NHS Foundation Trust | Co sponsors trial with | 2 |
| Cambridge University Hospitals NHS Foundation Trust | Co sponsors trial with | 2 |
Showing 5 of 46 relationships.
Latest dated events (51)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 51 events.
Biomarker capability evidence (28)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AR | Trial collaborator | Named in trial inclusion criteria |
| CSF2 | Trial sponsor | Named in trial inclusion criteria |
| CSF3 | Trial sponsor | Named in trial inclusion criteria |
| DEGS1 | Trial collaborator | Named in trial inclusion criteria |
| F2 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 28 evidence rows.
Biomarkers this organization publishes on (133)
Shown in this order: most publications first.
Showing 5 of 133 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.